Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Padcev Approved for Bladder Cancer in China: Astellas
Astellas Pharma said on August 20 that its antibody-drug conjugate Padcev (enfortumab vedotin) is now approved in China for the treatment of certain patients with urothelial cancer, the most common type of bladder cancer. The Chinese National Medical Products Administration’s…
To read the full story
Related Article
- Padcev Broadens Label for Keytruda Combo in China: Astellas
January 9, 2025
- Padcev Application Accepted for Review in China: Astellas
March 13, 2023
BUSINESS
- AstraZeneca CSO Urges Global Drug Price “Rebalancing” amid MFN Push
July 8, 2026
- JB to Build New Plant in Hokkaido to Double Ig Production
July 8, 2026
- Padcev/Keytruda Accepted for China Review in Perioperative MIBC
July 8, 2026
- Japan Ethical Drug Sales Fall 1.1% in May: Crecon
July 8, 2026
- Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…